Obesity Drug MariTide Achieves Up to 20% Weight Loss in Phase 2 Trial
Amgen’s MariTide achieved up to 20% average weight loss at 52 weeks without hitting a plateau in individuals with obesity or overweight.
Related Articles
Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial
As tested in this study, there is no benefit to routine vitamin D supplementation in patients with indolent lymphoma treated with rituximab. These results have…
Motion-Tracking Brillouin Microscopy Detects Keratoconus Before It’s Clinically Evident
For the first time, researchers show that Brillouin microscopy can detect keratoconus in its early stages, before it becomes clinically evident.
Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial
Objective To assess the effect of contemporary menopausal hormone therapy on the risk of cardiovascular disease according to the route of administration and combination of…
The BMJ Appeal 2024-25: David Miliband on hospital attacks, Trump, and the International Rescue Committee in a “flammable world”
Former UK foreign secretary, now president of the International Rescue Committee, talks to Kamran Abbasi about hospital attacks in war, the US president elect, and…
Bioengineering | bioRxiv
bioRxiv – the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution
Animal Behavior and Cognition | bioRxiv
bioRxiv – the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
Mirikizumab was safe and effective as induction and maintenance treatment for patients with moderately-to-severely active Crohn’s disease who had intolerance, inadequate response, or loss of…
Why an Offline Nuclear Reactor Led to Thousands of Hospital Appointments Being Canceled
Radioisotopes are a vital resource for imaging patients’ organs and tumors—but these unstable elements also suffer from an unstable supply chain.
AstraZeneca’s Enhertu included in China’s state insurance reimbursement
AstraZeneca’s blockbuster breast cancer drug will be added to China’s national reimbursement scheme list, according to an update from the National Healthcare Security Administration.
